GlassScriptPhysician profile
Thom Andrew Bunnell
NPI 1093754640
$10,234.71
in general payments reported to CMS, 2019-2025
56 companies · $1,739 in 2025
The $1,739 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $928 · 2020: $465 · 2021: $1,622 · 2022: $1,501 · 2023: $1,925 · 2024: $2,054 · 2025: $1,739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,702 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,701.95 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,429.59 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $1,067.51 | 2019-2025 | |
| Novo Nordisk INC | $913.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $887.16 | 2019-2025 | Farxiga, Bevespi Aerosphere, Fasenra |
| Glaxosmithkline, LLC. | $655.36 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $539.03 | 2019-2025 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Astellas Pharma US INC | $491.86 | 2021-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $392.90 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $344.97 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $323.40 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Lilly USA, LLC | $315.63 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $237.38 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $219.88 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.18 | 2019-2025 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $202.88 | 2023-2025 | Rexulti |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thom Bunnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.